首頁
Arrowhead Pharmaceuticals, Inc.

7月 2026Arrowhead Pharmaceutical...的市場佔有率分析

Watch and listen to a webinar on real-life insights about communicating with healthcare providers, coping with stress, supporting mental health and navigating social realities of FCS.

健康 > 生物技術和製藥

域名arrowheadpharma.com

成立年份1989

僱員501 - 1000

年度營收$200M - $500M

Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.（包含公司地區）

arrowheadpharma.com

查看更多網站流量與參與度資訊

Arrowhead Pharmaceuticals, Inc.截至 7月 2026 的總收入為 200M - 500M

Arrowhead Pharmaceuticals, Inc. 熱門網域產生的總收入

Arrowhead Pharmaceuticals, Inc. 熱門網域 3 年內的總收入

Arrowhead Pharmaceuticals, Inc. 熱門網域的總收入

arrowheadpharma.com200M - 500M

透過銷售情報查看更多內容

Arrowhead Pharmaceuticals, Inc.的熱門網域總造訪量

了解Arrowhead Pharmaceuticals, Inc.市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

arrowheadpharma.com55.1K

透過銷售情報查看更多內容

Arrowhead Pharmaceuticals, Inc.的熱門網域平均造訪時長

分析Arrowhead Pharmaceuticals, Inc.參與度指標。

過去 3 個月平均造訪時長

子公司細目

arrowheadpharma.com00:01:47

透過銷售情報查看更多內容

Arrowhead Pharmaceuticals, Inc.的熱門網域平均頁面瀏覽量

了解Arrowhead Pharmaceuticals, Inc.如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

arrowheadpharma.com2.79

透過銷售情報查看更多內容

Arrowhead Pharmaceuticals, Inc.按網域劃分的熱門競爭對手

7月 2026的熱門類似網站，依相似度排名

alnylam.com公司名Alnylam Pharmaceuticals僱員1001 - 5000總部美國, 馬薩諸塞州, Cambridge年度營收> $1B訪問總量117.4K科學與教育 > 生物學

使用的熱門技術Arrowhead Pharmaceuticals, Inc.

这些是Arrowhead Pharmaceuticals, Inc.顶级域名使用的行业网站技术

轉換與分析 (3)

Google Analytics

電子商務 (2)

WooCommerce

電子郵件服務 (2)

Microsoft Exchange Online

行動裝置 (2)

Meta Viewport

更多技術

10

檢視所有

新聞與訊號來自Arrowhead Pharmaceuticals, Inc.

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Arrowhead Pharmaceuticals, Inc. had revenue of $75.3M on Aug 4th '26.* Arrowhead missed on earnings but beat revenue expectations: The company reported a quarterly loss of $1.36 per share versus the $1.23 consensus estimate, while revenue reached $75.25 million, up 171% year over year and well above expectations.

新聞Arrowhead Pharmaceuticals, Inc. attended event Jefferies Global Healthcare Conference 2026 on Jun 7th '26.* Arrowhead Pharmaceuticals recently presented interim Phase 1/2a data for obesity and MASH candidate ARO-INHBE and new clinical findings for triglyceride-lowering therapy plozasiran, while also outlining upcoming clinical and commercial milestones during its Jefferies Global Healthcare Conference 2026 appearance.

新聞OliX Pharma identified as competitor of Arrowhead Pharmaceuticals, Inc. on Jun 4th '26.In the competitive RNAi landscape, OliX's OASIS platform competes indirectly with established GalNAc-siRNA developers including Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals in liver-targeted indications, while its locally administered dermatology programs occupy a less crowded segment with fewer direct clinical-stage competitors.